3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Neuroendocrine Tumors
60
Breast Neoplasms
22
Thyroid Neoplasms
20
Neoplasms
20
Multiple Endocrine Neoplasia Type 1
20
Carcinoma, Renal Cell
20
Melanoma
19
Carcinoma, Non-Small-Cell Lung
19
Adrenocortical Carcinoma
19
Small Cell Lung Carcinoma
17
Thyroid Cancer, Papillary
16
Colorectal Neoplasms
16
Thyroid Carcinoma, Anaplastic
15
Carcinoma, Neuroendocrine
15
Carcinoma, Medullary
14
Prostatic Neoplasms
13
Pheochromocytoma
13
Pancreatic Neoplasms
13
Lung Neoplasms
13
Carcinoma, Hepatocellular
13
Carcinoid Tumor
13
Insulinoma
12
Uterine Cervical Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Head and Neck Neoplasms
11
Adenocarcinoma, Follicular
11
Salivary Gland Neoplasms
10
Pituitary Neoplasms
10
Colonic Neoplasms
10
Interventions
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lethal Congenital Contracture Syndrome 2
×
Endocrine
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled